Similarly, addition of figitumumab to the standard regimen of docetaxel/prednisone seemed to have detrimental impact on clinical outcomes due to increased treatment‐related toxicity (eg hyperglycaemia, diarrhoea and asthenia), highlighting the challenges of improving the activity of docetaxel by targeting IGF1R.54 This evidence concerns the gene IGF1R and asthenia.